Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule medicines for genetically defined rare diseases with high unmet medical need. Its lead program, pociredir, is an oral HbF-inducing candidate being developed for sickle cell disease, while the company has also pursued other rare-disease programs such as losmapimod for FSHD through partnerships.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaPociredir and related clinical development activities for sickle cell disease.
Out-licensed or collaboration-based assets such as losmapimod and related rights.
Early-stage small-molecule programs for genetically defined rare diseases.
Asiakkaat
Fulcrum does not sell approved products today; its near-term counterparties are regulators, clinical investigators, and potential future commercialization partners rather than end-market patients. If its programs succeed, the eventual buyers would be specialty physicians, hospitals, and payors treating rare genetic diseases such as sickle cell disease and FSHD. The company also relies on collaboration partners like Sanofi for ex-U.S. development and commercialization rights.
Patients with genetically defined rare diseases, especially sickle cell disease, are the eventual beneficiaries of approved therapies.
Hematologists and specialty centers would prescribe and administer therapies like pociredir if approved.
Partners such as Sanofi license regional rights and may fund development or commercialization.
Insurers and other payors determine access, pricing acceptance, and formulary placement for future products.
Hospitals, research centers, and investigators run the company’s clinical studies and generate development data.
Strategia
Fulcrum’s strategy is to advance pociredir through clinical development toward a registration-enabling trial and eventual approval in sickle cell disease. At the same time, it seeks to preserve capital through partnerships, licensing, and selective development choices while maintaining flexibility to fund operations through equity, debt, or collaboration proceeds.
This is the company’s lead value driver and the clearest path to a future approved product.
The company has no product revenue and must fund ongoing R&D until approval or partnering.
Licensing can reduce cash burn and create non-dilutive funding while retaining upside.
Maantiede
Fulcrum is headquartered in Cambridge, Massachusetts and operates as a U.S.-based clinical-stage biotech. Its development work is centered in the United States, while ex-U.S. commercialization rights for losmapimod were previously licensed to Sanofi, showing a partnership model for geographic expansion. The company currently has no product-sales geography because it has not yet commercialized an approved medicine.
Riskit
Fulcrum is exposed to the binary risks of clinical-stage drug development, including trial failure, regulatory delays, and the possibility that its lead program never reaches approval. It also faces financing risk because it has no product revenue and will need additional capital to continue development, while competition from larger biotech and pharma companies could limit future market share and pricing power.
- Clinical development failure for pociredirVaikutus: KriittinenTodennäköisyys: Korkea
The company’s lead asset is still in development, so efficacy or safety setbacks could prevent approval.
Kohdistuu: Lead program in sickle cell disease
- Regulatory delay or adverse FDA feedbackVaikutus: KorkeaTodennäköisyys: Korkea
The next trial design depends on FDA meeting minutes and regulatory alignment.
Kohdistuu: Pociredir development timeline
- Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
The company has no product sales and expects to fund operations through external capital.
Kohdistuu: Cash runway and future R&D spend
- Competitive pressure in sickle cell diseaseVaikutus: KeskitasoTodennäköisyys: Matala
Approved gene therapies and other emerging treatments may capture physicians and payors first.
Kohdistuu: SCD market access and adoption
- Partner dependence and collaboration terminationVaikutus: KeskitasoTodennäköisyys: Matala
Out-licensed programs can be terminated or reprioritized by partners, reducing future economics.
Kohdistuu: Sanofi and future licensing deals
Kirjanpito
Harkinnanvaraiset erätUpfront payments and any future milestones must be allocated and recognized based on the contract terms.
Vaikutus: Affects reported revenue and R&D expense offsets
Trial costs are estimated before invoices are finalized, creating judgment in expense recognition.
Vaikutus: Can shift quarterly operating loss and comparability
When a program is suspended or terminated, related assets and deferred costs may need reassessment.
Vaikutus: May create write-downs or lower future expense capitalization
The company depends on external funding to continue operations and may need to revise runway assumptions.
Vaikutus: Important for assessing financing risk and continuity
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Incyte Corporation
INCY · Services-Commercial Physical & Biological Research
Incyte is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes proprietary medicines.
Vincerx Pharma, Inc.
Pharmaceutical Preparations
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
Monopar Therapeutics
MNPR · Pharmaceutical Preparations
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers.
Fulgent Genetics, Inc.
FLGT · Services-Medical Laboratories
Foghorn Therapeutics Inc.
FHTX · Pharmaceutical Preparations
Päivitetty: 24.9.2026